Long-Term Outcomes of Occipital Nerve Stimulation for New Daily Persistent Headache With Migrainous Features.
Chronic headache
chronic migraine
new daily persistent headache
occipital nerve stimulation
Journal
Neuromodulation : journal of the International Neuromodulation Society
ISSN: 1525-1403
Titre abrégé: Neuromodulation
Pays: United States
ID NLM: 9804159
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
04
07
2020
received:
18
04
2020
accepted:
27
07
2020
pubmed:
1
10
2020
medline:
1
9
2021
entrez:
30
9
2020
Statut:
ppublish
Résumé
New daily persistent headache (NDPH) is a subset of chronic headache where the pain is continuous from onset. Phenotypically it has chronic migraine or chronic tension type features. NDPH is considered to be highly refractory. Occipital nerve stimulation (ONS) has been used for treatment of refractory chronic migraine but there are no specific reports of its use for NDPH with migrainous features. Nine patients with NDPH with migrainous features were identified as having had ONS implants between 2007 and 2014 in a specialist unit with experience of using ONS in chronic migraine. Moderate to severe headache days were compared at baseline and follow-up. A positive response was defined as at least 30% reduction in monthly moderate to severe headache days. Patients had suffered NDPH for a median of 8 years (range 3-16 years) and had failed a median of 11 previous treatments (range 8-15). After a median follow-up of 53 months (range 27-108 months), only a single patient showed a positive response to ONS. At no point did the cohort as a whole show any change in monthly moderate to severe headache days or disability scores. Our experience suggests that ONS is not effective in the treatment of NDPH with migrainous features even in centers with experience in treating chronic migraine with ONS. The difference in response rates of chronic migraine and NDPH with migrainous features supports the concept of a different pathophysiology to the two conditions.
Identifiants
pubmed: 32996695
doi: 10.1111/ner.13282
pii: S1094-7159(21)06215-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1093-1099Informations de copyright
© 2020 The Authors. Neuromodulation: Technology at the Neural Interface published by Wiley Periodicals LLC on behalf of International Neuromodulation Society.
Références
Vanast WJ, Edmondton M. New daily persistent headaches definition of a benign syndrome. Program abstracts of the twenty-eighth Annual Meeting of the American Association for the Study of Headache June 27, 28 and 29, 1986, Chicago, Illinois U.S.A. Headache 1986;26:309-321.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2018;38:1-211.
Rozen TD. New daily persistent headache: an update. Curr Pain Headache Rep 2014;18:431.
Robbins MS, Grosberg BM, Napchan U, Crystal SC, Lipton RB. Clinical and prognostic subforms of new daily-persistent headache. Neurology 2010;74:1358-1364.
Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia 2004;24:955-959.
Prakash S, Saini S, Rana KR, Mahato P. Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India. J Headache Pain 2012;13:477-485.
Chen YF, Bramley G, Unwin G et al. Occipital nerve stimulation for chronic migraine-a systematic review and meta-analysis. PLoS One 2015;10:e0116786.
Dodick DW, Silberstein SD, Reed KL et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2015;35:344-358.
Lipton R, Goadsby PJ, Cady R et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine. Cephalalgia 2009;29:30.
Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011;31:271-285.
Silberstein SD, Dodick DW, Saper J et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2012;32:1165-1179.
Miller S, Watkins L, Matharu M. Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients. J Headache Pain 2016;17:68.
Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 2006;26:1168-1170.
Silberstein S, Tfelt-Hansen P, Dodick DW et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484-495.
Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia 2004;24:1-160.
Peng KP, Fuh JL, Yuan HK, Shia BC, Wang SJ. New daily persistent headache: should migrainous features be incorporated? Cephalalgia 2011;31:1561-1569.
Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia 2002;22:66-69.
Rozen TD. New daily persistent headache: clinical perspective. Headache 2011;51:641-649.
Miller S, Lagrata S, Matharu M. Multiple cranial nerve blocks for the transitional treatment of chronic headaches. Cephalalgia 2019;39:1488-1499.
Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol 2012;11:708-719.
Rozen TD. Triggering events and new daily persistent headache: age and gender differences and insights on pathogenesis-a clinic-based study. Headache 2016;56:164-173.
Vanast WJ, Diaz-Mitoma F, Tyrrell DL. Hypothesis: chronic benign daily headache is an immune disorder with a viral trigger. Headache 1987;27:138-142.
Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache 2007;47:1050-1055.
Saxon A. CSF TNFalpha has not been shown to be elevated in headache patients. Headache 2015;55:1266.
Rozen TD, Roth JM, Denenberg N. Cervical spine joint hypermobility: a possible predisposing factor for new daily persistent headache. Cephalalgia 2006;26:1182-1185.
Goadsby PJ, Boes C. New daily persistent headache. J Neurol Neurosurg Psychiatry 2002;72:ii6-ii9.
Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999;39:190-196.
Grande RB, Aaseth K, Lundqvist C, Russell MB. Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache. Cephalalgia 2009;29:1149-1155.